• 3/16/2006
  • Dedham, MA
  • press release
  • PharmaLive (www.pharmalive.com)

Signet Laboratories, Inc., a leading medical diagnostics/research company specializing in the development of monoclonal antibodies and diagnostic assays for cancer, infectious disease, and neurodegenerative disease, today announced the availability of two new monoclonal antibodies, EGFR, clone F4 and VEGF, clone VG-1.

EGFR, clone F4, has been implicated in the development and progression of a number of human solid tumors including lung, breast, prostate, colon, ovary, head, and neck.

VEGF, clone VG-1, is a secreted glycoprotein that is a potent and specific mitogen for vascular endothelial cells that stimulates angiogenesis during embryonic development and tumor formation.

Signet’s EGFR and VEGF antibodies offer researchers a valuable tool for cancer research. These antibodies complement Signet’s current product portfolio which includes markers such as D2-40, Cyclin D1, Cyclin E, HE4, and Hepsin.

About Signet Laboratories, Inc.

Signet Laboratories, Inc. (Signet, Dedham, MA) is a leading medical diagnostics/research company specializing in the development of monoclonal antibodies and diagnostic assays for cancer, infectious disease, and neurodegenerative disease.